These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer. Asrani K; Torres AF; Woo J; Vidotto T; Tsai HK; Luo J; Corey E; Hanratty B; Coleman I; Yegnasubramanian S; De Marzo AM; Nelson PS; Haffner MC; Lotan TL J Pathol; 2021 Dec; 255(4):425-437. PubMed ID: 34431104 [TBL] [Abstract][Full Text] [Related]
7. Author Correction: Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis. Conteduca V; Ku SY; Fernandez L; Dago-Rodriquez A; Lee J; Jendrisak A; Slade M; Gilbertson C; Manohar J; Sigouros M; Wang Y; Dittamore R; Wenstrup R; Mosquera JM; Schonhoft JD; Beltran H NPJ Precis Oncol; 2021 Sep; 5(1):84. PubMed ID: 34518634 [No Abstract] [Full Text] [Related]
8. Current advances of targeting epigenetic modifications in neuroendocrine prostate cancer. Cheng WC; Wang HJ Tzu Chi Med J; 2021; 33(3):224-232. PubMed ID: 34386358 [TBL] [Abstract][Full Text] [Related]
9. HOXB5 Overexpression Is Associated with Neuroendocrine Differentiation and Poor Prognosis in Prostate Cancer. Sekino Y; Pham QT; Kobatake K; Kitano H; Ikeda K; Goto K; Inoue S; Hayashi T; Shiota M; Yasui W; Teishima J Biomedicines; 2021 Jul; 9(8):. PubMed ID: 34440097 [TBL] [Abstract][Full Text] [Related]
10. Epigenetics in prostate cancer: clinical implications. Conteduca V; Hess J; Yamada Y; Ku SY; Beltran H Transl Androl Urol; 2021 Jul; 10(7):3104-3116. PubMed ID: 34430414 [TBL] [Abstract][Full Text] [Related]
11. An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Davies A; Nouruzi S; Ganguli D; Namekawa T; Thaper D; Linder S; Karaoğlanoğlu F; Omur ME; Kim S; Kobelev M; Kumar S; Sivak O; Bostock C; Bishop J; Hoogstraat M; Talal A; Stelloo S; van der Poel H; Bergman AM; Ahmed M; Fazli L; Huang H; Tilley W; Goodrich D; Feng FY; Gleave M; He HH; Hach F; Zwart W; Beltran H; Selth L; Zoubeidi A Nat Cell Biol; 2021 Sep; 23(9):1023-1034. PubMed ID: 34489572 [TBL] [Abstract][Full Text] [Related]
12. Prospective assessment of AR splice variant and PSMA detection on circulating tumor cells of mCRPC patients: preliminary analysis of patients enrolled in PRIMERA trial (NCT04188275). Francolini G; Loi M; Salvestrini V; Mangoni M; Detti B; Di Cataldo V; Aquilano M; Pinzani P; Salvianti F; Desideri I; Mariotti M; Garlatti P; Stocchi G; Ciccone LP; Lucidi S; Salvatore G; Sottili M; Meattini I; Livi L Clin Exp Metastasis; 2021 Oct; 38(5):451-458. PubMed ID: 34410545 [TBL] [Abstract][Full Text] [Related]
13. The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Risbridger GP; Clark AK; Porter LH; Toivanen R; Bakshi A; Lister NL; Pook D; Pezaro CJ; Sandhu S; Keerthikumar S; Quezada Urban R; Papargiris M; Kraska J; Madsen HB; Wang H; Richards MG; Niranjan B; O'Dea S; Teng L; Wheelahan W; Li Z; Choo N; Ouyang JF; Thorne H; Devereux L; Hicks RJ; Sengupta S; Harewood L; Iddawala M; Azad AA; Goad J; Grummet J; Kourambas J; Kwan EM; Moon D; Murphy DG; Pedersen J; Clouston D; Norden S; Ryan A; Furic L; Goode DL; Frydenberg M; Lawrence MG; Taylor RA Nat Commun; 2021 Aug; 12(1):5049. PubMed ID: 34413304 [TBL] [Abstract][Full Text] [Related]
14. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386 [TBL] [Abstract][Full Text] [Related]
15. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility. Modlin IM; Kidd M; Falconi M; Filosso PL; Frilling A; Malczewska A; Toumpanakis C; Valk G; Pacak K; Bodei L; Öberg KE Ann Oncol; 2021 Nov; 32(11):1425-1433. PubMed ID: 34390828 [TBL] [Abstract][Full Text] [Related]
16. Validation of Cell-Free RNA and Circulating Tumor Cells for Molecular Marker Analysis in Metastatic Prostate Cancer. Ladurner M; Wieser M; Eigentler A; Seewald M; Dobler G; Neuwirt H; Kafka M; Heidegger I; Horninger W; Bektic J; Klocker H; Obrist P; Eder IE Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440208 [TBL] [Abstract][Full Text] [Related]
17. Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers. Mao N; Zhang Z; Lee YS; Choi D; Rivera AA; Li D; Lee C; Haywood S; Chen X; Chang Q; Xu G; Chen HA; de Stanchina E; Sawyers C; Rosen N; Hsieh AC; Chen Y; Carver BS Nat Commun; 2021 Aug; 12(1):5053. PubMed ID: 34417459 [TBL] [Abstract][Full Text] [Related]
18. CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition. Lawrence MG; Porter LH; Choo N; Pook D; Grummet JP; Pezaro CJ; Sandhu S; Ramm S; Luu J; Bakshi A; Goode DL; Sanij E; Pearson RB; Hannan RD; Simpson KJ; Taylor RA; Risbridger GP; Furic L Mol Cancer Ther; 2021 Nov; 20(11):2140-2150. PubMed ID: 34413130 [TBL] [Abstract][Full Text] [Related]
19. Risk Signature of Cancer-Associated Fibroblast-Secreted Cytokines Associates With Clinical Outcomes of Breast Cancer. Sun C; Wang S; Zhang Y; Yang F; Zeng T; Meng F; Yang M; Yang Y; Hua Y; Fu Z; Li J; Huang X; Wu H; Yin Y; Li W Front Oncol; 2021; 11():628677. PubMed ID: 34395236 [TBL] [Abstract][Full Text] [Related]
20. Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level. Zhang Y; Zhang D; Meng Q; Liu Z; Xie H; Liu L; Xu F; Chen X BMC Cancer; 2021 Aug; 21(1):918. PubMed ID: 34388989 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]